PURPOSE: To determine long-term survival and predictors of recurrence in a retrospective cohort of @entity1 with @entity43 treated with intraperitoneal (IP) chemotherapy. @entity1 AND METHODS: Records were reviewed of 433 @entity1 who received IP therapy for @entity43 between 1984 and 1998; follow-up data were available for 411 @entity1 . IP therapy was provided as consolidation therapy (n = 89), or for treatment of persistent (n = 310) or recurrent (n = 12) disease after surgery and initial systemic therapy; therapy usually consisted of @entity902 -based combination therapy. Statistical analysis included tests for associations between potential prognostic factors, and between prognostic factors and survival. Survival probabilities were estimated by Kaplan-Meier methods, and prognostic factors for survival were evaluated by a Cox proportional hazard model. RESULTS: The mean age of @entity1 was 52 years (range, 25 to 76 years). Distribution by stage and grade was as follows: stage I, 7; II, 24; III, 342; IV, 52; not available (NA), 8; and grade 1, 30; 2, 99; and 3, 289; NA, 15. The median survival from initiation of IP therapy by residual disease was none, 8.7 years; microscopic, 4.8 years; less than 1 cm, 3.3 years; more than 1 cm, 1.2 years. In a multivariate analysis, the only significant predictors of long-term survival were grade and size of residual disease at initiation of IP therapy. CONCLUSION: Prolonged survival was observed in selected @entity1 receiving IP @entity902 -based therapy. It is not possible to determine the contribution of IP therapy to survival in this study. A relationship between size of disease at the initiation of IP therapy and long-term survival was demonstrated.

Intraperitoneal chemotherapy for XXXX : results of long-term follow-up.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer', 'epithelial ovarian cancer'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']
@entity43 :: (MESH:D010051,Disease) :: ['ovarian carcinoma']
